Introduction to background
Cefepime, an antibiotic of the fourth generation of enzymes, was developed by Bristol-Myers Squibb (BMS) in the 1990s. It has a broad antibacterial spectrum and shows antibacterial activity for both gebrane and gerranopositive bacteria, including intestinal coliform, coliformella, copper characterium, pneumococcus, golden grapepluccus, pneumococcus and septella.
Research and development background
With the widespread use of antibiotics, the problem of drug resistance has come to the fore, especially in the case of multiple strains of drug-resistant strains, such as non-morbid bacteria, which exposes clinical doctors to drug-free and difficult situations. The research and development of the head is designed to meet this challenge and provide a new treatment option.
Extensive antibacterial spectrum.
Both the gills have good antibacterial activity, including higher β-nimide stability than third-generation cystasy. It is effective against aerobics and gland positives, such as coli, pneumocococcal, and copper green pseudosynx.
Stability versus β-nimide
An important advantage of the hair gill is its stability of β-NIA, which makes it particularly effective in the treatment of infections caused by bacteria that produce ESBLs (super-wide β-NIA). This is particularly important in the treatment of infections caused by bacteria such as gavine intestinal bacterium, which often produce enzymes capable of hydrolysis of a wide range of β-nimide antibiotics.
Antibacterial activity
The antibacterial activity of the skull is mainly caused by inhibiting the synthesis of bacterial cells. It is resistant to various bacteria, including bacterial strains that are resistant to other antibiotics.
Medicokinetic properties
The hair gill is widely distributed in the body and can achieve effective therapeutic concentrations in a variety of body fluids, including aqueous fluids, urine, cholesterol, perimen fluids, sapiles and prostate fluids. The half-life was approximately 2.6 hours, with a total clearance rate of 120 ml/min, which was excreted mainly through kidneys, most of which were excreted in original form, and plasma proteins ranging from 15 to 19 per cent.
Clinical applications
Capricorn is mainly used to treat infections caused by sensitive bacteria such as lower respiratory tract infections, skin and skin structure infections, urinary tract infections and sepsis. Because of its extensive antibacterial spectrum and its good pharmacokinetic properties, the skull is an important drug for the treatment of serious infections.
Research and development experience
The research and development history of the head is a reflection of the continuing exploration and innovation of new antibiotics in the pharmaceutical industry. This process involved a large number of laboratory studies, clinical trials and pharmacological ergonomic assessments, from the initial findings of the antibiotic sapulactone to the development of the fourth generation.
Drug resistance
Despite the extensive antibacterial activity of the skull, drug resistance remains a challenge. For example, studies have shown that gavage intestinal bacterium is less sensitive to the gill than gill, suggesting the existence and spread of drug-resistant genes.
Conclusions
As a fourth-generation antibiotic, the research and development history of the tiara shows historical and scientific progress in the development of antibiotics. It not only provides a powerful anti-infection tool for clinical purposes, but also reminds us of the severity of drug resistance and the importance of the ongoing development of new antibiotics. As global attention to antibiotic resistance increases, the rational use of antibiotics, such as the capricorn, and the development of new drugs will become more critical.
